Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449520 | 0.68 | HTT (0.65) | PIN1HTTALDH1A1L3MBTL1HPGD | |
| SCHEMBL23674190 | 0.62 | TACR1 (0.42) | PIN1FFAR2CYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL23766637 | 0.62 | ALPI (0.53) | CYP1A2HSD17B10L3MBTL1 | |
| SCHEMBL23839864 | 0.61 | NAALAD2 (0.44) | PIN1HTTFFAR2CYP2D6NAALAD2 | |
| SCHEMBL2118063 | 0.60 | PPARG (0.50) | CYP1A2HSD17B10 | |
| SCHEMBL1193057 | 0.60 | PPARG (0.50) | CYP1A2HSD17B10 | |
| SCHEMBL3740070 | 0.60 | ALPI (0.44) | CYP1A2L3MBTL1 | |
| SCHEMBL3740060 | 0.60 | ALPI (0.44) | CYP1A2L3MBTL1 | |
| SCHEMBL23295309 | 0.60 | KMT2A (0.41) | HTTHSD17B10ALDH1A1L3MBTL1HPGD | |
| SCHEMBL20817266 | 0.60 | ERCC5 (0.50) | ALDH1A1L3MBTL1MMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | PIN1 870/4885KEAP1 2555/4885HTT 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.